Board of Directors

Mr. Koven has served as a member of the board of directors of Kala Pharmaceuticals, Inc. since September 2017 and as Lead Independent Director since December 2018. He was, until his retirement in January 2019, the President and Chief Business Officer of Aralez Pharmaceuticals Inc., and served in that role with the company’s predecessor, Pozen Inc., commencing in June 2015. Prior to joining Pozen, Mr. Koven was Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc. from February 2012 until January 2015, when it was acquired by Endo International plc. Before that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc. from July 2010 until May 2011, when it was acquired by Merck & Co., Inc. Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. from March 2007 until February 2010, when it was acquired by Dainippon Sumitomo Pharma Co., Ltd.(now Sunovion.) Prior to that, he was Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc. from August 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006. Mr. Koven began his career in the pharmaceutical industry first as an Assistant General Counsel and then as Associate General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York, and from 1992 to 1993, he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S. 

Mr. Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and Bachelor of Arts Degree in Political Science from Dalhousie University.

Prior to his appointment as Chief Executive Officer and President of the Company, Mr. Kim was the General Counsel and a Senior Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs and Mr. Kim has been serving as a member of the Company’s Board since July 2021. Mr. Kim previously served as Executive Director of Dong-A ST from 2018 through 2020 and as Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. During his time at Dong-A ST and Dong-A Socio Holdings, he negotiated many significant transactions, including licensing and investment transactions. Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private, Swiss-based provider of scientific research and development services. Mr. Kim previously served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. He received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.

Mr. Groves has served as Executive Vice President and General Counsel of Medifast, Inc. since November 2011, and as the company’s Corporate Secretary since June 2015. Mr. Groves was a director of the company from 2009 to 2015. He served as an independent director and member of the Audit Committee from 2009 to 2011 and on the Executive Committee from 2011 to 2015. Prior to joining Medifast, from 2003 to 2011, Mr. Groves was Assistant Vice President of Government Affairs for Verizon Maryland, which he joined as a Senior Staff Consultant in 2001. Mr. Groves is a United States Army veteran. He was a direct commissioned Judge Advocate in the United States Army Judge Advocate General’s (JAG) Corp. As a JAG Officer, he practiced law and had the distinction of prosecuting criminal cases in the District Court of Maryland as a Special Assistant United States Attorney. Over the course of three years, he received two Army Achievement Medals, and one Army Commendation Medal.

Mr. Groves is a member of the New Jersey and District of Columbia bars, as well as several bar associations.

Mr. Strickland has served in numerous leadership roles throughout his career, including, most recently, as the Chairman of Ampex Corporation, where he previously served as CEO from February 2007 until March 2012.

Prior to Ampex, he was the president and CEO of Cardiff Holdings from March 2012 until August 2013, the chairman of Medical Resources from September 1997 until January 2011, the president and CEO of MCSi, Inc. from March 2003 until March 2004, the president and CEO of Capitol Wire, Inc. from September 1999 until August 2002 and had leadership roles with Kerr Group from June 1986 until August 1997, including serving as the president and CEO, and as Senior Vice President, Finance and Chief Financial Officer. 

He previously served as a member of the Board of Directors of eCommission and Applied Technical Services, and as a US Naval Officer.
Mr. Strickland received a Master of Business Administration, Finance from the Wharton School of the University of Pennsylvania and a Bachelor of Arts, Economics from Yale University.

Mr. Salsbury is an attorney with nearly 30 years of experience as a senior executive with public and private companies and in private law practice. Since September 2017, Mr. Salsbury has served as Counsel to Verisma Systems, Inc., a provider of cloud-based automated disclosure management systems. From February 2013 to July 2017, he was Secretary and General Counsel to Best Doctors, Inc., a provider of expert medical opinions.

Mr. Salsbury earned a B.A from Dartmouth College and J.D and M.B.A. degrees from the University of Virginia.

Mr. Glickman has over 30 years of experience in the pharmaceutical and medical device industry, where he began his life sciences career as a diagnostic sales representative and progressed in roles of increasing responsibility to senior executive positions. Mr. Glickman was most recently the Co-Chief Executive officer for TherapeuticsMD, Inc. from 2022 through the sale of the company's assets to Mayne Therapeutics in January 2023. Prior to this role, he served as Chief Business Officer, Commercial of TherapeuticsMD, Inc. since June 2021. Previously, from April 2018 until December 2020, Mr. Glickman was the Chief Commercial Officer for Esperion Therapeutics, Inc., where he developed and led the commercial division in the launch of the company's first cardiovascular prescription therapy. From June 2015 to March 2018, Mr. Glickman served as the Chief Commercial Officer for Aralez Pharmaceuticals Inc., where he built out and led the first commercial effort for a previously clinical organization. Prior to this, he was Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals (Endo Pharmaceuticals), during which time, he led all commercial efforts for a portfolio of 13 pharmaceutical products. Mr. Glickman's previous positions include Senior Vice President of Sales and Marketing and Vice President of Medical Devices for Otsuka America Pharmaceuticals Inc., and marketing head, Regional Sales Director and Vice President of Sales and Operations at Kos Pharmaceuticals (a subsidiary of Abbott Laboratories), where he expanded his skills in the commercial products area.

Mr. Glickman received a Bachelor of Arts in Political Science from the State University of New York Oswego, and a Master of Business Administration in Finance and International Management from New York University's Stern School of Business.

Dr. James P. Tursi is the Executive Vice President of Global Research and Development for Endo Pharmaceuticals. He is responsible for leading strategy and driving execution across Endo’s three business pillars: Branded Pharmaceuticals, Sterile Injectables and durable Generic Pharmaceuticals.

Prior to joining industry, Dr. Tursi practiced medicine and surgery for over 10 years and created I Will Pass®, a medical education company which assisted physicians with board certification. In pharma, he has 20 years of R&D and commercialization experience specializing in urology, orthopedics, microbiome, women’s health, men’s health, plastic surgery / cosmetic medicine and drug-device applications.

He began his industry career holding roles of increasing responsibility at Procter & Gamble Pharmaceuticals and GlaxoSmithKline Biologicals followed by Chief Medical Officer (CMO) roles in innovative biopharmaceutical companies. Just prior to Endo, James was Chief Scientific Officer of Ferring Pharmaceuticals U.S.

During his tenure as CMO, Dr. Tursi and his team’s successful initiation and execution of several development programs through all phases of development has resulted in multiple FDA approvals, initiated device innovation efforts and he's work was supportive of the $2.6 billion acquisition of Auxilium Pharmaceuticals by Endo Pharmaceuticals and the $960 million acquisition of Antares Pharma by Halozyme Therapeutics.

Dr. Tursi holds a Bachelor of Science in Chemistry and Biology from Ursinus College, a Doctor of Medicine from the Medical College of Pennsylvania and completed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital.

Dr. Tursi is also currently a member of the Ideal Image (www.Idealimage.com) Board of Directors.